PolyMedix is focused on developing novel therapeutic drugs for serious, life-threatening acute disorders.
Our therapeutic targets are cardiovascular thrombosis disorders and infectious diseases. We have created our entire product pipeline ourselves using a proprietary computational technology platform developed at and licensed from the University of Pennsylvania. The first two products are a novel antibiotic drug and a unique heparin antagonist.